• 1
    Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359362.
  • 2
    World Health Organisation. Hepatitis C: global prevalence – update. Wkly Epidemiol Rec 1997;72:341344.
  • 3
    Alter MJ, Kruszon-Moran D, Nainan OV et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556562.
  • 4
    Booth JCL, O’Grady J, Neuberger J. Clinical guidelines on the management of hepatitis C. Gut 2001;49(Suppl I): i1i21.
  • 5
    Alter MJ. Epidemiology of hepatitis C. Hepatology 1997;26:62s65s.
  • 6
    Ramsay ME, Balogun MA, Harris HE. Epidemiology and health burden of hepatitis C in the UK. In: BassendineM, FosterG, MilesA, eds. The effective management of hepatitis C infection. London: Aesculapius, 2003: 1529.
  • 7
    Judd A, Hickman M, Jones S et al. Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study. Br Med J 2005;330:2425.
  • 8
    Simmonds P, Alberti A, Alter HJ et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994;19:13211324.
  • 9
    Rai R, Wilson LE, Astemborski J, Ananaia F et al. Severity and correlates of liver disease in hepatitis C virus-infected injection drug users. Hepatology 2002;35:12471255.
  • 10
    Ryder SD. The natural history of hepatitis C infection. In: BassendineM, FosterG, MilesA, eds. The effective management of hepatitis C infection. London: Aesculapius, 2003:314.
  • 11
    Kanai K, Kako M, Okamoto H. HCV genotypes in chronic hepatitis C and response to interferon. Lancet 1992;339:1543.
  • 12
    Tsubota A, Chayama K, Ikeda K et al. Factors predictive of response to interferon-therapy in hepatitis C virus infection. Hepatology 1994;19:10881094.
  • 13
    Alberti A, Morsila G, Chemello L et al. Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV. Lancet 1992;340:697698.
  • 14
    Ryder SD. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut 2004;53:451455.
  • 15
    Sobesky R, Mathurin P, Charlotte F et al. Modelling the effect of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group. Gastroenterology 1999;116:378386.
  • 16
    McCaughan GW, George J. Fibrosis progression in chronic hepatitis C virus infection. Gut 2004;53:318321.
  • 17
    Wright M, Goldin R, Fabre AM et al. Measurement and determinants of the natural history of liver fibrosis in hepatitis c virus infection. Gut 2003;52:574579.
  • 18
    Bataller R, North KE, Brenner DA. Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology 2003;37:493502.
  • 19
    Fattovich G, Giustina G, Degos F et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;1112:436472.
  • 20
    Tsukuma H, Hiyama T, Tanaka S et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Eng J Med 1993;328:17971801.
  • 21
    Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in the quality of life in the absence of cirrhosis. Hepatology 1998;27:209212.
  • 22
    Wessely S, Pariente C. Fatigue, depression and chronic hepatitis C infection. Psychol Med 2002;32:110.
  • 23
    Forton DM, Thomas HC, Murphy CA et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology 2002;35:433439.
  • 24
    Forton DM, Allsop JM, Main J, Foster GR, Thomas HC, Taylor-Robinson SD. Evidence for a cerebral effect of the hepatitis C virus. Lancet 2001;358:3839.
  • 25
    Kramer L, Bauer E, Funk G et al. Subclinical impairment of brain function in chronic hepatitis C infection. J Hepatol 2002;37:349354.
  • 26
    Radkowski M, Wilkinson J, Nowicki M et al. Search for hepatitis C virus negative strand RNA sequences and analysis of viral sequences in the central nervous system: evidence of replication. J Virol 2002;76:600608.
  • 27
    Hadziyannis S. Non hepatic manifestations of chronic HCV infection. J Viral Hepat 1997;4:117.
  • 28
    Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:11471171.
  • 29
    National Institutes of Health Consensus Development Conference statement: management of hepatitis C: 2002 – June 10–12, 2002. Hepatology 2002;36:s3s20.
  • 30
    Puoti M, Zonaro A, Ravaggi A, Marin MG, Castelnuovo F, Cariani E. Hepatitis C virus RNA and antibody response in the clinical course of acute hepatitis C virus infection. Hepatology 1992;16:877881.
  • 31
    Pawlotsky JM. Use and interpretation of virological tests for hepatitis C. Hepatology 2002;36(Suppl 1):S65S73.
  • 32
    Rice P. Screening and lab diagnosis of HCV. Acta Neuropsychiatrica 2006 [In press].
  • 33
    Alberti A, Chumeck N, Collins S et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005;42:615624.
  • 34
    Terjung B, Lemnitzer I, Dumoulin FL et al. Bleeding complications after percutaneous liver biopsy. An analysis of risk factors. Digestion 2003;67:138145.
  • 35
    Regev A, Berho M, Jeffers LJ et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002;97:26142618.
    Direct Link:
  • 36
    The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994;20:1520.
  • 37
    Afdhal NH, Nunes D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol 2004;99:11601174.
    Direct Link:
  • 38
    Joseph AE, Saveryuttu SH, Al-Sam S, Cook MG, Maxwell JD. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clin Radiol 1991;43:2631.
  • 39
    Castera L, Vergniol J, Foucher J et al. Prospective comparison of transient elastography, FibroTest, APRI and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128:343350.
  • 40
    Lim AKP, Taylor-Robinson SD, Patel N et al. Hepatic vein transit times using a microbubble agent can predict disease severity non-invasively in patients with hepatitis C. Gut 2005;54:128133.
  • 41
    Robaeys G, Buntinx F, Bottieau E et al. Guidelines for the management of chronic hepatitis C in patients infected after substance abuse. Acta Gatroenterol Belg 2005;68:3845.
  • 42
    Herrine SK, Friedman LS. Divining the role of liver biopsy in hepatitis C. J Hepatol 2005;43:374376.
  • 43
    Green ST, Mohsen AH, McKendrick MW et al. Potential for hepatitis C transmission among non-needle/syringe sharing Sheffield drug injectors through the sharing of drug preparation paraphernalia. Commun Dis Public Health 2001;4:3841.
  • 44
    Edlin BR. Prevention and treatment of hepatitis C in injection drug users. Hepatology 2002;36(Suppl 1): S210S219.
  • 45
    Gotz HM, Van Doornum G, Niesters HG, Den Hollander JG, Thio HB, De Zwart O. A cluster of acute hepatitis C virus infection among men who have sex with men – results from contact tracing and public health implications. AIDS 2005;19:969974.
  • 46
    Akahane Y, Kojima M, Sugai Y et al. Hepatitis C virus infection in spouses of patients with type C chronic liver disease. Ann Intern Med 1994;51:338343.
  • 47
    Ohto H, Terazawa S, Sasaki N et al. Transmission of hepatitis C virus from mothers to infants. N Eng J Med 1994;330:744750.
  • 48
    Giovanni M, Tagger A, Ribero ML et al. Maternal-infant transmission of hepatitis C virus and HIV infections: a possible interaction. Lancet 1990;335:1166.
  • 49
    Resti M, Azarri C, Galli L et al. Maternal drug use is a pre-eminent risk factor for mother-to-child hepatitis C virus transmission: results from a multicentre study of 1372 mother-infant pairs. J Infect Dis 2002;185:567572.
  • 50
    Ogasawara S, Kage M, Kosai K-I et al. Hepatitis C virus RNA in saliva and breastmilk of hepatitis C carrier mothers. Lancet 1993;341:561.
  • 51
    Vento S, Garofano T, Rezini C et al. Fulminant hepatitis associated with hepatitis A superinfection in patients with chronic hepatitis C. N Eng J Med 1998;338:286290.
  • 52
    Tsai JF, Jeng JE, Ho MS, Chang WY, Lin ZY, Tsai JH. Independent and additive effect modification of hepatitis B and C virus infection on the development of chronic hepatitis. J Hepatol 1996;24:271276.
  • 53
    UK Health Departments. Immunisation against infectious disease. London: HMSO, 1996.
  • 54
    McGregor J, Marks PJ, Hayward A, Bell Y, Slack RCB. Factors influencing hepatitis B vaccine uptake in injecting drug users. J Public Health Med 2003;25:165170.
  • 55
    Wiley TE, McCarthy M, Breide L, McCarthy M, Layden JT. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology 1998;28:805809.
  • 56
    Pessione F, Degos F, Marcellin P et al. Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology 1998;27:17171722.
  • 57
    Powell EE, Johnson JR, Clouston AD. Steatosis: co-factor in other liver diseases. Hepatology 2005;42:513.
  • 58
    Bressler BL, Guindi M, Tomlinson G, Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003;38:639644.
  • 59
    Seef LB, Miller RN, Rabkin CS et al. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 2000;132:105111.
  • 60
    Marcellin P, Boyer N, Gervais A et al. Long-term histological improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-α therapy. Ann Intern Med 1997;127:875881.
  • 61
    Hoofnagle JH, Mullen KD, Jones DB et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Eng J Med 1986;315:15751578.
  • 62
    Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon alpha-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352:14261432.
  • 63
    Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Eng J Med 2002;347:975982.
  • 64
    Manns MP, McHutchinson JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of hepatitis C: a randomised trial. Lancet 2001;358:958965.
  • 65
    Hadziyannis SJ, Sette H, Morgan TR et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin combination therapy in chronic hepatitis C: randomized study of the effect of treatment duration and ribavirin dose. Ann Intern Med 2004;130:346355.
  • 66
    Hasan F, Asker H, Al-Khaldi J et al. Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. Am J Gastroenterol 2004;99:17331737.
    Direct Link:
  • 67
    Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Eng J Med 2004;350:22652271.
  • 68
    Backmund M, Meyer K, Von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology 2001;34:188193.
  • 69
    Jowett SL, Agarwal K, Smith BC et al. Managing chronic hepatitis C acquired through intravenous drug use. Q J Med 2001;94:153158.
  • 70
    Mauss S, Berger F, Goelz J, Jacob B, Schmutz G. A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance. Hepatology 2004;40:120124.
  • 71
    Edlin BR, Seal KH, Lorvick J et al. Is it justifiable to withhold treatment for hepatitis C from illicit drug users? N Eng J Med 2001;345:211214.
  • 72
    Sheerin IG, Green FT, Sellman JD. What is the cost-effectiveness of hepatitis C treatment for injecting drug users on methadone maintenance in New Zealand? Drug Alcohol Rev 2004;23:261272.
  • 73
    Miller NH. Compliance with treatment regimes in chronic asymptomatic diseases. Am J Med 1997;102:4349.
  • 74
    McHutchinson JG, Manns M, Patel K et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002;123:10611069.
  • 75
    Cournot M, Glibert A, Castel F et al. Management of hepatitis C in active drug users: experience of an addiction care hepatology unit. Gastroenterol Clin Biol 2004;28:533539.
  • 76
    De Bie J, Robaeys G, Buntinx F. Hepatitis C, interferon alpha and psychiatric co-morbidity in intravenous drug users (ivdu): guidelines for clinical practice. Acta Gastroenterol Belg 2005;68:6880.
  • 77
    Golub ET, Latka M, Hagan H et al. Screening for depressive symptoms among HCV-infected injection drug users: examination of the utility of the CES-D and the Beck Depression Inventory. J Urban Health 2004;81:278290.
  • 78
    Mehta SH, Cox A, Hoover DR et al. Protection against persistence of hepatitis C. Lancet 2002;359:14781483.
  • 79
    Davis GL, Rodrigue JR. Treatment of chronic hepatitis C in active drug users. N Eng J Med 2001;345:215217.
  • 80
    Dalgard O, Bjoro K, Hellum K et al. Treatment of chronic hepatitis C in injecting drug users: 5 years’ follow-up. Eur Addict Res 2002;8:4549.
  • 81
    Everson GT. Management of cirrhosis due to chronic hepatitis C. J Hepatol 2005;42:S65S74.
  • 82
    Ryder SD. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut 2003;52(Suppl III):iii1iii8.
  • 83
    Bruix J, Sherman M, Llovet JM et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001;35:421430.
  • 84
    Heathcote EJ, Shiffman ML, Cooksley WG et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Eng J Med 2000;343:16731680.
  • 85
    Everson GT. Treatment of patients with hepatitis C virus on the waiting list. Liver Transpl 2003;9:905915.
  • 86
    Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002;8:350355.
  • 87
    Mackie J, Groves K, Hoyle A et al. Orthotopic liver transplantation for alcoholic liver disease: a retrospective analysis of survival, recidivism, and risk factors predisposing to recidivism. Liver Transpl 2001;7:418427.
  • 88
    Levenson JL, Olbrisch ME. Psychosocial evaluation of organ transplant candidates: a comparative survey of process, criteria, and outcomes in heart, liver, and kidney transplantation. Psychosomatics 1993;34:314323.
  • 89
    Weinrieh RM, Barnett R, Lynch KG, DePiano M, Atanda A, Olthoff KM. A matched comparison study of medical and psychiatric complications and anaesthesia and analgesia requirements in methadone-maintained liver transplant recipients. Liver Transpl 2004;10:97106.
  • 90
    Poynard T, Regimbeau C, Myers RP et al. Interferon for acute hepatitis C. Cochrane Database Syst Rev 2002; 1; CD000369.
  • 91
    Jaeckel E, Cornberg M, Wedemeyer H et al. Treatment of acute hepatitis C with interferon alfa-2b. N Eng J Med 2001;345:14521457.
  • 92
    Villano SA, Vlahov D, Nelson KE et al. Persistence of viraemia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999;29:908914.
  • 93
    Gerlach JT, Diepolder HM, Zachoval R et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003;125:8088.
  • 94
    Jauncey M, Micallef JM, Gilmour S et al. Clearance of hepatitis C virus after newly acquired infection in injection drug users. J Infect Dis 2004;190:12701274.
  • 95
    Broers B, Helbling B, Francois A et al. Barriers to interferon-α therapy are higher in intravenous drug users than in other patients with acute hepatitis C. J Hepatol 2005;42:323328.
  • 96
    Clarke SM, Mulcahy FM. What’s new for injection drug users with HIV infection? Sex Transm Infect 2003;79:8083.
  • 97
    Benhamou Y, Bochet M, Di Martino V et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hepatology 1999;30:10541058.
  • 98
    Torriani FJ, Rodriguez-Torres M, Rockstroh JK et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Eng J Med 2004;351:438450.
  • 99
    Chung RT, Andersen J, Volberding P et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Eng J Med 2004;351:451459.